Head-to-head evidence
PF-06439535 vs Zirabev (bevacizumab-bvzr)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
PF-06439535
Marketed by Pfizer
NCT02364999 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial with 719 participants, using tumor response by RECIST as its primary clinical endpoint. PF-06439535 had a confirmed response rate of 45.3% versus 44.6% with European bevacizumab, and the prespecified equivalence margins were met, supporting a strong evidence grade.
Zirabev (bevacizumab-bvzr)
Marketed by Pfizer
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PF-06439535's landscape · Zirabev (bevacizumab-bvzr)'s landscape